Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes

Korábbi kezelés

• Started medications within 3 months prior to Screening that may cause significant weight change, including, but not limited to, tricyclic antidepressants, atypical antipsychotics, mood stabilizers, and phentermine.
• Unstable weight defined as self-reported change in body weight exceeding 5% within the 3 months prior to Screening.
• Known clinically significant gastric-emptying abnormality or chronic treatment with medications that directly affect gastrointestinal motility.

Más betegség

• Current diagnosis or history of diabetes mellitus.
• Family or personal history of multiple endocrine neoplasia Type 2 or medullary thyroid cancer.
• Uncontrolled hypertension or unstable cardiovascular disease.
• History of chronic or acute pancreatitis.
• History of suicide attempt.
• History of significant active or unstable Major Depressive Disorder (MDD) or other severe psychiatric disorder.

Laborértékek

• Received treatment with semaglutide, tirzepatide, glucagon-like peptide-1 receptor (GLP-1R) agonist, GLP-1/glucose-dependent insulinotropic polypeptide (GIP), or glucagon receptor agonist within 3 months prior to Screening.
  • Note: Additional inclusion/exclusion criteria may apply, per protocol.

• BMI ≥35 kilograms per square meter (kg/m\^2).
• History of being unresponsive to at least 1 self-reported effort to lose weight with diet and/or exercise in the last 6 months.